Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat to Be Filed in US in Early 2021
Akebia Therapeutics’ oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor vadadustat, which is under codevelopment with Otsuka Pharmaceutical outside Japan, hit its primary and secondary efficacy endpoints in its two multinational PIII studies in adult patients on dialysis with anemia due…
To read the full story
Related Article
- Otsuka Ends Vadadustat Global License Deal with Akebia
May 16, 2022
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat Nixed in US
April 1, 2022
- Otsuka Files HIF-PH Inhibitor Vadadustat in Europe
November 1, 2021
- FDA Target Date for Vadadustat Set for March 29: Otsuka/Akebia
June 2, 2021
- Otsuka Partner Akebia Files HIF-PH Inhibitor Vadadustat in US
March 31, 2021
- Akebia/Otsuka's Vadadustat Hits Primary Target in Multinational PIII
May 8, 2020
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…